Takuma Narita

5PUBLICATIONS
22CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Radiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Aug 15, 2026
Visualizing Baseline Eligibility Across Locally Advanced or Metastatic Urothelial Cancer Trials and Real-World Cohorts.

|May 16, 2022
Single immediate instillation of chemotherapy is associated with decreased recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer who receive adjuvant induction bacillus Calmette-Guérin therapy.

Naoki Fujita, Shingo Hatakeyama, Masaki Momota

|Apr 01, 2022
Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma.

Kyo Togashi, Shingo Hatakeyama, Tohru Yoneyama

|Mar 01, 2022
Editorial Comment to Comparative oncological outcomes after radical prostatectomy or external beam radiation therapy plus androgen deprivation therapy in men with clinical T3b prostate cancer.

Takuma Narita, Shingo Hatakeyama, Chikara Ohyama

|Sep 22, 2021
Characteristics of α2,3-sialyl N-glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level.

Tohru Yoneyama, Hayato Yamamoto, Mihoko Sutoh Yoneyama

Pageof 1

Frequent Collaborators

5 joint publications

Shingo Hatakeyama

3 joint publications

Hayato Yamamoto

2 joint publications

Tohru Yoneyama

2 joint publications

Yuki Tobisawa